| Verteporfin PDT for non-standard indications--a review of current literature. | |
| | |
MedLine Citation:
|
PMID: 20162298 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Verteporfin photodynamic therapy (PDT) is approved for the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD), as well as for subfoveal CNV due to pathologic myopia and ocular histoplasmosis syndrome. Verteporfin PDT addresses the underlying pathology of ocular vascular disorders through its angio-occlusive mechanism of action, which reduces both visual acuity loss and the underlying leakage associated with lesions. Verteporfin PDT has also been associated with encouraging treatment outcomes in case studies involving patients with choroidal vascular disorders such as polypoidal choroidal vasculopathy, central serous chorioretinopathy, choroidal haemangioma, angioid streaks, and inflammatory CNV, i.e. conditions currently considered as non-standard indications of verteporfin PDT. In many studies, outcomes were better than expected based on the natural courses of each of these conditions. Although the anti-vascular endothelial growth factor (VEGF) therapies, ranibizumab and pegaptanib, have been approved for CNV due to AMD, their role in these other choroidal vascular disorders remains to be established. We summarize current literature that has documented the use of verteporfin PDT in these conditions. CONCLUSIONS: The complex pathogenesis of CNV provides a rationale for investigating combination approaches comprising verteporfin PDT and anti-VEGF therapies. Randomized controlled studies are warranted to confirm the preliminary results of verteporfin PDT as a monotherapy or in combination with anti-VEGF therapies in the treatment of a variety of choroidal vascular conditions. |
| | |
Authors:
|
Wai Man Chan; Tock-Han Lim; Alfredo Pece; Rufino Silva; Nagahisa Yoshimura |
Related Documents
:
|
11523938 - A comparison of the sensitivity of aptt reagents to the effects of enoxaparin, a low-mo... 6116428 - Biotin in clinical medicine--a review. 1052268 - "short and long-term therapies in psychosomatic disorders". 14714898 - New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases. 19762898 - Evaluation and treatment of inflammatory myopathies. 21955378 - Autoimmune bullous skin diseases. part 1: clinical manifestations. |
Publication Detail:
|
Type: Journal Article; Review Date: 2010-02-17 |
Journal Detail:
|
Title: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie Volume: 248 ISSN: 1435-702X ISO Abbreviation: Graefes Arch. Clin. Exp. Ophthalmol. Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-03-29 Completed Date: 2010-06-23 Revised Date: 2013-05-20 |
Medline Journal Info:
|
Nlm Unique ID: 8205248 Medline TA: Graefes Arch Clin Exp Ophthalmol Country: Germany |
Other Details:
|
Languages: eng Pagination: 613-26 Citation Subset: IM |
Affiliation:
|
Department of Ophthalmology, HK Sanatorium Hospital, Happy Valley, Hong Kong. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angioid Streaks
/
drug therapy Central Serous Chorioretinopathy / drug therapy Choroid Diseases / drug therapy* Choroid Neoplasms / drug therapy Choroidal Neovascularization / drug therapy Hemangioma / drug therapy Humans Peripheral Vascular Diseases / drug therapy Photochemotherapy* Photosensitizing Agents / therapeutic use* Porphyrins / therapeutic use* Retinal Diseases / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Photosensitizing Agents; 0/Porphyrins; 129497-78-5/verteporfin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Thrombophilic risk factors in the pathogenesis of non-arteritic anterior ischemic optic neuropathy p...
Next Document: Ultrasonic Doppler measurements of blood flow velocity of rabbit retinal vessels using a 45-MHz need...